9 of the Top 10 Pharma Manufacturers Adopt Redi Health, But Compliance Questions Remain
Sage Growth Partners surveyed 100 pharmaceutical, biopharmaceutical, and life sciences leaders in early 2026. The findings show that 81% believe patients increasingly expect consumer-grade experiences from pharmaceutical companies and their support programs.
Meanwhile, 52% said traditional patient support vendors have moved too slowly, while 68% credited newer providers with pushing the industry forward. Therefore, manufacturers are looking beyond fragmented portals and disconnected service providers toward unified digital platforms.
Nearly 70% of Therapy Abandonment Happens Early; Pharma Turns to Unified Patient Platforms
Patient support programs help patients manage access, affordability, and adherence. Yet many programs still depend on separate technologies and vendors that do not work smoothly together.
According to the research, nearly 70% of therapy abandonment occurs before month three. Major drop-off points appear after prescription, before first patient contact, between program enrollment and first fill, and during the first three months of treatment.
As a result, pharma leaders want platforms that support two-way communication, simple enrollment and consent, personalized guidance, consistent multichannel experiences, and rapid escalation to human teams.
Consumer-Grade Patient Support Is Growing, Can It Still Meet GxP Compliance?
Consumer-style convenience alone cannot answer every pharmaceutical requirement. When platforms manage consent, patient communications, program records, or safety-related information, manufacturers must consider data integrity, controlled access, traceability, system changes, vendor qualification, and regulatory review.
In addition, two-way communication can create pharmacovigilance responsibilities when patients report adverse events or product complaints. Companies must define how the platform captures, transfers, escalates, and documents those reports.
These questions make a structured computerized system lifecycle important. Zamann Pharma has addressed similar challenges through a computerized system validation framework aligned with GAMP 5, EU Annex 11, and FDA 21 CFR Part 11.
Redi Health Reports 34% Higher Medication Fills and Faster PSP Enrollment
Redi Health says its platform gives patients one place to access support services, affordability programs, medication education, and adherence resources. The company reports 34% higher medication fills, 33% additional enrollment in support programs, and up to a 10% reduction in first-fill abandonment.
Moreover, Redi Health reports that 61% of patients remain on therapy at six months and that enrollment can take two minutes or less. The company says it has worked with medical, legal, and regulatory review committees across more than 20 manufacturers.
Digital Patient Support Is Expanding, Data Integrity and Vendor Oversight Must Keep Pace
The findings suggest that pharma companies no longer see patient experience and digital infrastructure as separate priorities. Instead, they need platforms that improve access and engagement while supporting governance, documented oversight, and controlled workflows.
Zamann Pharma’s Digital Solutions for GMP-Regulated Operations service helps pharmaceutical teams improve compliant digital workflows, computerized systems, and data management. Explore how structured digital support can strengthen operational efficiency and compliance readiness.
Source: Fiercepharma.Com